1
|
Riffault B, Cloarec R, Rabiei H, Begnis M, Ferrari DC, Ben-Ari Y. A quantitative cholinergic and catecholaminergic 3D Atlas of the developing mouse brain. Neuroimage 2022; 260:119494. [PMID: 35870696 DOI: 10.1016/j.neuroimage.2022.119494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Accepted: 07/19/2022] [Indexed: 10/17/2022] Open
Abstract
The complex organization of brain regions during development requires a three-dimensional approach to facilitate the visualization and quantification of dynamic changes taking place throughout this important period. Using the tissue clearing method combined with immunohistochemistry, three-dimensional (3D) lightsheet microscopy and a multiresolution registration technique, we provide the first 3D atlases of the main cholinergic (CH) and catecholaminergic (CA) systems in the mouse brain from embryonic day 12 (E12) to post-natal day 8 (P8). We report that in several brain structures, there is a logarithmic scale increase of choline acetyltransferase and tyrosine hydroxylase positive neurons from E18 to P8. In addition, a detailed voxel-wise analysis revealed abrupt modifications in the developmental trajectory of many brain structures during the transition from E18 to P0. Our atlases will not only facilitate developmental studies aimed at quantitatively determining the fate of CH or CA neurons in utero but also be used as an anatomical reference to quantify other neuronal populations present in the annotated regions. In the future, these maps will be a reliable tool to study developmental malformations associated with neurological and psychiatric disorders.
Collapse
Affiliation(s)
- B Riffault
- Neurochlore, Campus scientifique de Luminy, Marseille, France
| | - R Cloarec
- Neurochlore, Campus scientifique de Luminy, Marseille, France
| | - H Rabiei
- B & A Biomedical, Campus scientifique de Luminy, Marseille, France
| | - M Begnis
- Neurochlore, Campus scientifique de Luminy, Marseille, France
| | - D C Ferrari
- Neurochlore, Campus scientifique de Luminy, Marseille, France
| | - Yehezkel Ben-Ari
- Neurochlore, Campus scientifique de Luminy, Marseille, France; B & A Biomedical, Campus scientifique de Luminy, Marseille, France
| |
Collapse
|
2
|
Cloarec R, Riffault B, Dufour A, Rabiei H, Gouty-Colomer LA, Dumon C, Guimond D, Bonifazi P, Eftekhari S, Lozovaya N, Ferrari DC, Ben-Ari Y. Pyramidal neuron growth and increased hippocampal volume during labor and birth in autism. Sci Adv 2019; 5:eaav0394. [PMID: 30746473 PMCID: PMC6357736 DOI: 10.1126/sciadv.aav0394] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/08/2018] [Accepted: 12/10/2018] [Indexed: 06/09/2023]
Abstract
We report that the apical dendrites of CA3 hippocampal pyramidal neurons are increased during labor and birth in the valproate model of autism but not in control animals. Using the iDISCO clearing method, we show that hippocampal, especially CA3 region, and neocortical volumes are increased and that the cerebral volume distribution shifts from normal to lognormal in valproate-treated animals. Maternal administration during labor and birth of the NKCC1 chloride transporter antagonist bumetanide, which reduces [Cl-]i levels and attenuates the severity of autism, abolished the neocortical and hippocampal volume changes and reduced the whole-brain volume in valproate-treated animals. These results suggest that the abolition of the oxytocin-mediated excitatory-to-inhibitory shift of GABA actions during labor and birth contributes to the pathogenesis of autism spectrum disorders by stimulating growth during a vulnerable period.
Collapse
Affiliation(s)
- R. Cloarec
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Zone Luminy Biotech Entreprises, 13288 Cedex 09 , Marseille, France
| | - B. Riffault
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Zone Luminy Biotech Entreprises, 13288 Cedex 09 , Marseille, France
| | - A. Dufour
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Zone Luminy Biotech Entreprises, 13288 Cedex 09 , Marseille, France
| | - H. Rabiei
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Zone Luminy Biotech Entreprises, 13288 Cedex 09 , Marseille, France
| | - L.-A. Gouty-Colomer
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Zone Luminy Biotech Entreprises, 13288 Cedex 09 , Marseille, France
| | - C. Dumon
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Zone Luminy Biotech Entreprises, 13288 Cedex 09 , Marseille, France
| | - D. Guimond
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Zone Luminy Biotech Entreprises, 13288 Cedex 09 , Marseille, France
| | - P. Bonifazi
- Biocruces Health Research Institute, Barakaldo, Spain & IKERBASQUE: The Basque Foundation for Science, Bilbao, Spain
| | - S. Eftekhari
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Zone Luminy Biotech Entreprises, 13288 Cedex 09 , Marseille, France
| | - N. Lozovaya
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Zone Luminy Biotech Entreprises, 13288 Cedex 09 , Marseille, France
| | - D. C. Ferrari
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Zone Luminy Biotech Entreprises, 13288 Cedex 09 , Marseille, France
| | - Y. Ben-Ari
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Zone Luminy Biotech Entreprises, 13288 Cedex 09 , Marseille, France
| |
Collapse
|